52 reports of this reaction
2.4% of all FLUMAZENIL reports
#10 most reported adverse reaction
DEPRESSED LEVEL OF CONSCIOUSNESS is the #10 most commonly reported adverse reaction for FLUMAZENIL, manufactured by Baxter Healthcare Corporation. There are 52 FDA adverse event reports linking FLUMAZENIL to DEPRESSED LEVEL OF CONSCIOUSNESS. This represents approximately 2.4% of all 2,155 adverse event reports for this drug.
Patients taking FLUMAZENIL who experience depressed level of consciousness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSED LEVEL OF CONSCIOUSNESS is a less commonly reported adverse event for FLUMAZENIL, but still significant enough to appear in the safety profile.
In addition to depressed level of consciousness, the following adverse reactions have been reported for FLUMAZENIL:
The following drugs have also been linked to depressed level of consciousness in FDA adverse event reports:
DEPRESSED LEVEL OF CONSCIOUSNESS has been reported as an adverse event in 52 FDA reports for FLUMAZENIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSED LEVEL OF CONSCIOUSNESS accounts for approximately 2.4% of all adverse event reports for FLUMAZENIL, making it a notable side effect.
If you experience depressed level of consciousness while taking FLUMAZENIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.